Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study.
OBJECTIVE
To evaluate the efficacy of 3 maintenance regimens (topical tazarotene, oral minocycline hydrochloride, or both) in sustaining improvement in acne.


METHODS
Multicenter, open-label treatment phase followed by double-blind, randomized, parallel-group maintenance phase.


METHODS
Ambulatory patients in research or referral centers.


METHODS
Volunteer sample of 189 patients with moderately severe to severe acne vulgaris (110 entered maintenance phase, 90 completed, and 2 discontinued because of adverse events).


METHODS
All patients were treated with 0.1% tazarotene gel (each evening) and a 100-mg capsule (twice daily) of minocycline hydrochloride for up to 12 weeks. Patients with 75% or greater global improvement at week 12 were randomly assigned to 12 weeks of maintenance therapy with tazarotene gel plus placebo capsules, vehicle gel plus minocycline capsules, or tazarotene gel plus minocycline capsules.


METHODS
Overall disease severity, global improvement, and lesion counts.


RESULTS
All regimens were effective in sustaining improvements in acne. After 12 weeks of maintenance therapy, the mean reductions from baseline in noninflammatory and inflammatory lesion count, respectively, were 60% and 54% with tazarotene, 52% and 66% with minocycline, and 64% and 66% with tazarotene plus minocycline. At week 24, more than 80% of patients in each group had maintained a 50% or greater global improvement from baseline, and more than 50% had maintained a 75% or greater global improvement.


CONCLUSIONS
A high percentage of patients with moderately severe to severe acne can maintain improvement in their condition with topical retinoid monotherapy. Maintenance with combination tazarotene and minocycline therapy showed a trend for greater efficacy but no statistical significance vs tazarotene alone. Topical retinoid monotherapy should be considered for maintenance to help minimize antibiotic exposure.
Leyden
James
J
Skin Study Center, Broomall, PA, USA. jjleyden@mindspring.com
Thiboutot
Diane M
DM
Shalita
Alan R
AR
Webster
Guy
G
Washenik
Kenneth
K
Strober
Bruce E
BE
Shupack
Jerome
J
D000152:Acne Vulgaris / Q000188:drug therapy* / Q000473:pathology; D000284:Administration, Oral; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008911:Minocycline / Q000008:administration & dosage / Q000627:therapeutic use*; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014481:United States; D012176:Retinoids
D000900:Anti-Bacterial Agents; D003879:Dermatologic Agents; D008911:Minocycline; D009539:Nicotinic Acids; C086827:tazarotene; D012176:Retinoids